BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 32919903)

  • 1. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
    Bernstein JA; Tyson C; Relan A; Adams P; Magar R
    J Manag Care Spec Pharm; 2020 Feb; 26(2):203-210. PubMed ID: 31841366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
    Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
    J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icatibant as acute treatment for hereditary angioedema in adults.
    Farkas H
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
    J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
    Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
    J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for the diagnosis and treatment of hereditary angioedema].
    Marković AS; Rozmanić V; Anić B; Aberle N; Racić G; Novak S; Sunara D; Grdinić B; Karadza-Lapić L; Radas MR; Karanović B; Kvenić B
    Lijec Vjesn; 2014; 136(5-6):117-29. PubMed ID: 25154179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
    BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAE update: determining optimal patient specific therapy.
    Gower RG
    Allergy Asthma Proc; 2013; 34(1):7-12. PubMed ID: 23406928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
    Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Management of Hereditary Angioedema Attacks.
    Katelaris CH
    Immunol Allergy Clin North Am; 2017 Aug; 37(3):541-556. PubMed ID: 28687108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches in hereditary angioedema.
    Antoniu SA
    Clin Rev Allergy Immunol; 2011 Aug; 41(1):114-22. PubMed ID: 21279474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
    Wu MA; Zanichelli A; Mansi M; Cicardi M
    Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
    Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.